Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSe-Hoon Lee
About this trial
This study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
Eligibility criteria
Qualifiers
aged above or equal to 18
Histologically confirmed lung cancer patients
Patient treated with immune checkpoint inhibitor
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Se-Hoon Lee
Lead sponsor
Samsung Medical Center
Sponsor institution
Source ClinicalTrials.gov